Valuation dashboard for Lexaria Bioscience Corp. (LEXX) with P/E N/A, P/B 1.08, EV/EBITDA -0.43 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Lexaria Bioscience Corp. is a biotechnology company focused on advanced drug delivery. Its proprietary and patented DehydraTECH technology is designed to significantly improve the oral delivery of active pharmaceutical ingredients, enhancing their absorption into the bloodstream.
Valuation Ratios
| Price / Book | 1.08 |
| EV / EBITDA | -0.43 |
| Dividend Yield | 0.00% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| LEXX | Lexaria Bioscience Corp. | $5M | 1.08 | -160.7% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.6B | 29.76 | 6.46 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price
| Price | $3.10 |
| Market Cap | $5M |
| Exchange | NASDAQ |
| Country | CA |
Profitability
| Return on Equity | -160.72% |
| Return on Invested Capital | -173.96% |
| Return on Assets | -161.71% |
| Gross Margin | 100.00% |
| Operating Margin | -3973.16% |
| Net Margin | -3985.58% |
Explore sector: Healthcare · Biotechnology
More sections of LEXX: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks